Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486

NCT03493646 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER_GOV

Sponsor class

Conditions

Myelodysplastic Syndromes
Acute Myeloid Leukemia
Chronic Myelomonocytic Leukemia

Interventions

DRUG: Azacitidine
DRUG: CC-486

Sponsor

Kirby Institute

Collaborators

[object Object]